Clinical Trials Browser

Phase 2 × Kidney Neoplasms × tislelizumab × Clear all

NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms